PDSB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

PDS Biotechnology Corp · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.69 USD
0.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -22.0% below the Trend Line and sits at 17.2% of its 52-week range. The latest completed week returned 0.7%, after a -19.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 12 out of 100
Latest Close 0.69 USD 31 Jul 2026
1W Return 0.7% latest completed week
4W Return -19.6% short-term follow-through
12W Return -45.1% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.7% Latest completed week; four-week move -19.6%. Indicator stack 10/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.56% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 379.0%. News sentiment 52/100 61 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -22.0% below the Trend Line and sits at 17.2% of its 52-week range. The latest completed week returned 0.7%, after a -19.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3512-week average 0.50

12-week confirmation

Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.35Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -19.6% over four weeks, -45.1% over 12 weeks, and -37.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.7%
4W-19.6%
12W-45.1%
26W-17.6%
52W-37.1%
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.02Latest activity-pressure read.
Pressure change-2049.5%Four-week change in activity pressure.
Leadership-32.05Latest relative-leadership reading.
RS change-41.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength45/100Blend of value, momentum, and quality. Underlying universe rank 56; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum48/100Medium-term price momentum. Underlying universe rank 53; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

PDSB shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 379.0%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move379.0%
Put/call volume0.00
Pressure100
Speculation0
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 61 relevant articles.

11 positive · 47 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move379.0%Nearest-chain priced movement where available.
52-week drawdown-55.7%Distance below the 52-week high.
13-week volatility10.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+70.1%Week of 10 Apr.
Worst week-31.3%Week of 24 Apr.
Latest week+0.7%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains2
Flat weeks0
Modest losses3
Sharp losses14
Recent vol10.0%13-week weekly-return volatility.
Base vol14.2%52-week weekly-return volatility.
Up/down split18/32Count of positive and negative weeks in the 52-week window.
Average skew12.9% / -7.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape14/100

Trend, activity pressure, participation, and risk combine to a 14/100 tape read.

 Indicator analysis47/100

Latest 12-week confirmation: trend 8/12, activity pressure 8/12, relative leadership 1/12.

Activity pressure 0.35; No reversal markers Next-Week ExpectancyNegative 42.56%

Next-week expectancy is negative with a 42.56% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

PDSB shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 379.0%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 379.0% Sentiment52/100

Weighted news tone is neutral across 61 relevant articles.

PDS Biotechnology Corp (PDSB) Valuation: PE, PB & Fair Value Analysis Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.69 USD0.7%0.88 USD2.46 USD-1.02-32.05845.6KOff
24 Jul 20260.68 USD-7.3%0.88 USD2.49 USD-0.87-33.00876.5KOff
17 Jul 20260.73 USD-5.0%0.89 USD2.52 USD-0.60-29.891.5MOff
10 Jul 20260.77 USD-9.3%0.90 USD2.55 USD-0.26-30.131.9MOff
3 Jul 20260.85 USD-4.0%0.90 USD2.58 USD0.05-22.731.2MOn
26 Jun 20260.89 USD-7.0%0.90 USD2.61 USD0.36-20.032.3MOn
19 Jun 20260.95 USD-9.0%0.90 USD2.63 USD0.63-19.223.6MOn
12 Jun 20261.05 USD2.9%0.89 USD2.66 USD0.91-10.743.6MOn
5 Jun 20261.02 USD-5.6%0.89 USD2.69 USD1.22-13.216.1MOn
29 May 20261.08 USD-10.0%0.88 USD2.73 USD1.36-13.995.0MOn
22 May 20261.20 USD-10.4%0.88 USD2.78 USD1.37-2.995.5MOn
15 May 20261.34 USD7.2%0.87 USD2.83 USD1.287.917.5MOn
8 May 20261.25 USD27.5%0.85 USD2.87 USD1.25-0.583.3MOn
1 May 20260.98 USD8.9%0.84 USD2.90 USD1.22-18.343.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.